Galectin Therapeutics (GALT) grants director 60,000 stock options

Rhea-AI Filing Summary

Galectin Therapeutics Inc. director Gilbert S. Omenn reported receiving a grant of derivative securities in the form of stock options. On January 16, 2026, he was awarded 60,000 stock options (right to buy) with a stated exercise price of $0 per share, all held in a direct ownership capacity. Following this grant, he beneficially owned 60,000 derivative securities linked to the company’s common stock. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and are scheduled to vest 100% on December 31, 2026, meaning they become fully exercisable on that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OMENN GILBERT S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	60,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 60,000 shares (Direct)

Footnotes (1)

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. The options vest 100% on December 31, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OMENN GILBERT S

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$0	01/16/2026		A		60,000		(2)	01/16/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

	Jack W. Callicutt, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Galectin Therapeutics (GALT) report?

Galectin Therapeutics reported that director Gilbert S. Omenn received a grant of 60,000 stock options (right to buy) on January 16, 2026, as shown in a Form 4 filing.

What are the key terms of the 60,000 stock options granted to the Galectin Therapeutics (GALT) director?

The Form 4 shows 60,000 stock options with an exercise price of $0 per share, directly owned by the director and issued under the 2019 Omnibus Equity Incentive Plan.

When do the Galectin Therapeutics (GALT) stock options granted to the director vest?

According to the footnotes, the 60,000 stock options granted to the director vest 100% on December 31, 2026, at which point they become fully exercisable.

How many derivative securities does the Galectin Therapeutics (GALT) director own after this Form 4 transaction?

After the reported grant, the director beneficially owns 60,000 derivative securities in the form of stock options tied to Galectin Therapeutics common stock.

Under which equity plan were the Galectin Therapeutics (GALT) stock options granted?

The footnotes state that the stock options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, which governs this grant.

Is the Galectin Therapeutics (GALT) Form 4 filing for a director or officer?

The reporting person, Gilbert S. Omenn, is listed as a director of Galectin Therapeutics Inc. and is not identified as an officer or 10% owner in the Form 4.